Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Amazon.com Inc (AMZN) vs Heron Therapeutics Inc (HRTX) Price & Performance

Amazon.com IncTrade
Heron Therapeutics IncTrade

Price performance (Past 24H)

Key statistics

Amazon.com Inc vs Heron Therapeutics Inc — how do they compare? Amazon.com Inc trades at $268.82 (market cap $2.94T), while Heron Therapeutics Inc trades at $0.35 (market cap $61.47M). The key difference: Amazon.com Inc is far larger — about 47828.2× Heron Therapeutics Inc's market cap, and Amazon.com Inc is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.

AMZNHRTX
Market Cap
$2.94T$61.47M
Volume
3,931,282
Sector
Consumer CyclicalHealth
52-Week High
$284.02$1.49
52-Week Low
$198.79$0.32
Enterprise Value
$3.04T$168.21M

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Amazon.com Inc

Amazon (AMZN) trades at $268.92, down 3.3% over the past 24 hours, but maintains strong fundamental momentum with revenue growing to $716.92 billion in 2025 and net income reaching $77.67 billion. The stock shows a bullish technical setup with moving averages supporting upward momentum, while analyst sentiment remains overwhelmingly positive with 89% buy ratings and a $333.86 consensus price target representing 24% upside potential.

Amazon's outlook remains favorable with accelerating AI-driven growth in AWS and expanding profit margins, though investors face risks from intense retail competition and substantial capital expenditures. The company's dominant market position and strong cash flow generation support continued expansion, but execution on massive infrastructure investments will be critical for sustained shareholder returns.

Heron Therapeutics Inc

HRTX trades at $0.3507, up 6.21% in the last 24 hours, but technical indicators signal a bearish trend overall. The company reported Q2 2026 revenue of $37.7 million, missing estimates, with a net loss per share of $0.03. Despite a high gross profit margin of 70.07%, negative net income and cash flow from operations highlight financial strain. Analyst consensus remains strongly bullish with 94.74% buy ratings, but recent news includes a Zacks Strong Sell designation on July 15, 2026.

The outlook is mixed: strong analyst support contrasts with weak earnings and bearish technicals. Investment opportunity lies in potential turnaround if revenue growth accelerates, but risks include persistent losses, competitive pressures, and reliance on financing activities. The stock faces significant downside if operational performance does not improve.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Amazon.com Inc

Amazon.com, Inc. is an online retailer that offers a wide range of products. The Company products include books, music, computers, electronics and numerous other products. Amazon offers personalized shopping services, Web-based credit card payment, and direct shipping to customers. Amazon also operates a cloud platform offering services globally.

Read more on AMZN

About Heron Therapeutics Inc

Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.

Read more on HRTX